Rafat Abonour, MD
Hematology · Indianapolis, INNPI 1750346755
Payments from drug & device makers
Across 715 payments — averaging $6855.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.5M
- Janssen Research & Development, LLC$721K
- Bristol Myers Squibb$669K
- GSK$383K
- Johnson & Johnson$377K
- AstraZeneca$372K
- plus $830K from 13 others
Across 2 payments — averaging $7355.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$10K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $1,549,908 |
| Janssen Research & Development, LLC | 51 | $720,593 |
| Bristol Myers Squibb | 56 | $668,535 |
| GSK | 65 | $382,814 |
| Johnson & Johnson(2 entities) | 284 | $377,075 |
| AstraZeneca | 13 | $371,996 |
| Takeda Pharmaceuticals U.S.A., Inc. | 129 | $358,947 |
| Genentech, Inc. | 9 | $297,933 |
| E.r. Squibb & Sons, L.L.C. | 30 | $94,143 |
| Pfizer | 35 | $59,957 |
| Regeneron Healthcare Solutions, Inc. | 5 | $7,622 |
| AbbVie | 4 | $5,470 |
| Adaptive Biotechnologies Corporation | 7 | $3,006 |
| Sanofi | 3 | $1,854 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Genmab U.S., Inc. | 1 | $124 |
| Gilead | 1 | $122 |
| Karyopharm Therapeutics Inc. | 2 | $114 |
| Legend Biotech USA Inc. | 2 | $79 |
How this compares
Too few hematology providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Indianapolis
- Luke AkardIndianapolis$3.9M
- Brandon HardestyIndianapolis$560K
- Felix MensahIndianapolis$358K
- Varun MittalIndianapolis$297K
- Fatemeh Ardeshir LarijaniIndianapolis$206K
- Jennifer SchwartzIndianapolis$51K
- Lalitha NayakIndianapolis$11K
- Kenneth OforiIndianapolis$51
- Rakesh MehtaIndianapolis$13
- Sherif FaragKokomo$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.